Completed PHASE2 INTERVENTIONAL 1-arm NCT03068416

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.

Sponsor: AFA Insurance

Conditions B-Cell Lymphoma B-cell Leukemia

Interventions CAR T cells

Updated 9 times since 2017 Last updated: Oct 14, 2021 Started: Sep 18, 2017 Primary completion: Aug 19, 2021 Completion: Aug 19, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on B-Cell Lymphoma and B-cell Leukemia, this trial is completed. The trial is conducted by AFA Insurance and has accumulated 9 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2021 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE2
May 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 4 earlier versions

Nov 2018 — May 2020 [monthly]

Recruiting PHASE2
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2017 — Oct 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AFA Insurance
Uppsala University
Uppsala University Hospital

Data source: Uppsala University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Uppsala, Sweden